Breathe Me

Physicians for Informed Consent (PIC) Updates Its 'Aluminum - Vaccine Risk Statement': Document Includes Data on Association Between Aluminum in Vaccines and Childhood Asthma

Retrieved on: 
Thursday, December 29, 2022
Wheeze, Informed consent, Personality, Food, Nervous system, Public health, Neurotoxicity, Human, Encephalopathy, VRS, Aluminium, Coma, CDC, Pain scale, Vaccination, Senate, Agency, Amnesia, Parent, Science, Academic Pediatrics, Disease, Pediatrics, ATSDR, Infection, Asthma, Seizure, HHS, FDA, Breathe Me, PIC, Statistics, Poison, Pharmaceutical industry, Vaccine, Physician

NEWPORT BEACH, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Physicians for Informed Consent ( PIC ) has released an update to its Aluminum  - Vaccine Risk Statement (VRS) titled "Aluminum in Vaccines: What Parents Need to Know."

Key Points: 
  • NEWPORT BEACH, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Physicians for Informed Consent ( PIC ) has released an update to its Aluminum  - Vaccine Risk Statement (VRS) titled "Aluminum in Vaccines: What Parents Need to Know."
  • The concise, two-page educational document — which serves to answer important questions about the risks of aluminum-containing vaccines — now includes important data about a study's link between aluminum in vaccines and asthma.
  • "Overexposure to aluminum may lead to significant harm," said Dr. Shira Miller, founder and president of Physicians for Informed Consent.
  • To read or download the educational document "Aluminum in Vaccines: What Parents Need to Know," please visit physiciansforinformedconsent.org/aluminum .

Practice Winter Wellness with Tips from Pediatric ENT and Dr. Noze Best Founder

Retrieved on: 
Wednesday, January 4, 2023
Medical Devices, Parenting, Infectious Diseases, Children, Baby, Maternity, Family, Health, Consumer, General Health, Wheeze, Hospital, Late, Degenerative disease, RSV, Child, Congestion, Alertness, COVID-19, Virus, Dehydration, Disease, ENT, Breathe Me, Learning, Mayo Clinic, Nose, Paracetamol, Suction, Parent, Lip, Human, Drinking, Clinical professor, Tears, Ibuprofen, Fever, Toy, Health insurance, Residential care

, esteemed pediatric ENT, and founder and Chief Medical Officer of Dr. Noze Best , shares his advice to help families practice wellness this winter—and year-round.

Key Points: 
  • , esteemed pediatric ENT, and founder and Chief Medical Officer of Dr. Noze Best , shares his advice to help families practice wellness this winter—and year-round.
  • “For infants and young children, respiratory illnesses can become very serious,” says Dr. Goudy.
  • As RSV and flu continue to spread this winter, parents can take steps to avoid hospital visits and keep their families well.
  • For more resources about treating RSV and other respiratory illnesses from Dr. Goudy and his team, visit www.drnozebest.com/blogs/the-doctor-is-in

Sobi Receives Approval from Health Canada for Empaveli™ (pegcetacoplan) for the Treatment of Certain Patients with Paroxysmal Nocturnal Hemoglobinuria

Retrieved on: 
Friday, December 9, 2022
Eculizumab, Thrombosis, Neurology, Breathe Me, Quality of life, Incidence, Toronto General Hospital, Blood, Hospital, Fatigue, Safety, Erectile dysfunction, McKinley, The New England Journal of Medicine, Swedish Orphan Biovitrum, PEGASUS, Nephrology, Pain, PNH, Geographic atrophy, Paroxysmal nocturnal hemoglobinuria, SEK, Hemolysis, The Amazing Race Canada 4, Degenerative disease, United Arab Emirates, Hematology, Nasdaq Stockholm, Anemia, Health Canada, Pharmaceutical industry, Sales, Patient, Pegcetacoplan, EU

PNH is characterized by the destruction of red blood cells (hemolysis) and release of free hemoglobin that can cause thrombosis and require frequent transfusions.

Key Points: 
  • PNH is characterized by the destruction of red blood cells (hemolysis) and release of free hemoglobin that can cause thrombosis and require frequent transfusions.
  • Empaveli is approved in the United States and the United Arab Emirates for the treatment of adults with PNH.
  • In Australia, Empaveli is approved for the treatment of adult patients with PNH who have an inadequate response to, or are intolerant of, a C5 inhibitor.
  • McKinley C. Extravascular Hemolysis Due to C3-Loading in Patients with PNH Treated with Eculizumab: Defining the Clinical Syndrome.

Optime Care, Specialty Pharmacy Patient Management Organization Announces Enhanced Partnership with Rigel Pharmaceuticals, Inc. for Rezlidhia™ Patients

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, FDA, Health, Family, Consumer, Other Health, Pharmaceutical, Oncology, Other Science, Research, Managed Care, Genetics, Science, Women, Recurrence, Liver, Hepatotoxicity, Cancer, Uric acid, Mucositis, Disease, Woman, AML, URAC, Hypertension, Potassium, Transaminase, Rash, Sodium, Azacitidine, Partnership, Degenerative disease, Knowledge, HUB, ACHC, Fatigue, Hypotension, Alkaline phosphatase, Clinical trial, Constipation, Fatality, Leukocytosis, Probability, Retinoic acid syndrome, Creatinine, AST, Diarrhea, Jaundice, Postcholecystectomy syndrome, Weight gain, Market access, Dexamethasone, Purging disorder, Edema, Case management (US healthcare system), Mutation, Acute kidney injury, Lymphocyte, Lipase, Disorder, IDH1, CYP3A, Patient, Myelocyte, Nausea, FDA, Hydroxycarbamide, ALT, Breathe Me, Arthralgia, Bilirubin, Accreditation Commission for Health Care, Acute myeloid leukemia, Pharmaceutical industry, Generic drug, Rigel, Fever

Scott Yohe, Vice President Market Access at Rigel Pharmaceuticals, says, We are excited to work with Optime Care in the complete management of our Rezlidhia patients.

Key Points: 
  • Scott Yohe, Vice President Market Access at Rigel Pharmaceuticals, says, We are excited to work with Optime Care in the complete management of our Rezlidhia patients.
  • If differentiation syndrome is suspected, withhold REZLIDHIA and initiate treatment with corticosteroids and hemodynamic monitoring until symptom resolution.
  • Of the 25 patients who experienced differentiation syndrome, 19 (76%) recovered after treatment or after dose interruption of REZLIDHIA.
  • Our experience with small patient populations, coupled with our strategic partnership with AscellaHealth , enhances our services and ability to serve the specialty pharmacy market.

Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)

Retrieved on: 
Thursday, December 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, QT, Hypersensitivity, ESR1, Hypocalcemia, Peripheral neuropathy, Anemia, Angioedema, Headache, AstraZeneca, Syncope, Woman, Duane syndrome, Hives, Xeroderma, Paced Auditory Serial Addition Test, Leukopenia, Sciatic nerve, Risk, Indigestion, Thrombocytopenia, Lung, Rash, Myalgia, Liver, Fatigue, Pain, Back pain, US Foods, Photopsia, Birth, Immunoassay, Constipation, Hair, Infant, Infection, Food, Neutropenia, Bleeding, Bradycardia, Pregnancy, Dysgeusia, Cough, Diarrhea, Estradiol, Itch, PFS, Tears, Neuralgia, CI, Purging disorder, Grade, Mutation, Xerostomia, Vertigo, Patient, Fulvestrant, Nausea, Vomiting, Incidence, Aromatase, Breathe Me, Arthralgia, Erythema, Bone pain, Stomatitis, Weakness, Sciatica, Fetus, Neuropathic pain, Appetite, Pharmaceutical industry, Vaccine, Dietary supplement, Fever

AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer.

Key Points: 
  • AstraZeneca has a broad clinical development program for camizestrant in advanced breast cancer.
  • Advise women of reproductive potential to use effective contraception during FASLODEX treatment and for 1 year after the last dose.
  • SERENA-2 is a randomized, open-label, parallel group, multicenter Phase II trial evaluating camizestrant at several dose levels compared to FASLODEX in advanced ER-positive, HER2-negative breast cancer.
  • The primary endpoints are PFS defined by response evaluation criteria in solid tumors (RECIST) version 1.1 for 75mg camizestrant versus FASLODEX and for 150mg camizestrant versus FASLODEX.

Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer

Retrieved on: 
Thursday, December 8, 2022
Oncology, Health, General Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, QT, Indigestion, Thrombocytopenia, ORR, Hypersensitivity, Neutropenia, Rash, Bleeding, Xerostomia, Pregnancy, Dysgeusia, Cough, Hypocalcemia, Vertigo, Patient, Diarrhea, Peripheral neuropathy, Estradiol, OS, Myalgia, Anemia, Liver, Angioedema, Itch, Nausea, Fulvestrant, Neuralgia, Headache, Tears, Fatigue, Vomiting, Syncope, Pain, Back pain, Appetite, Breathe Me, Woman, Incidence, Arthralgia, Erythema, Bone pain, Birth, Stomatitis, Duane syndrome, Hives, Immunoassay, Constipation, Safety, Purging disorder, Hair, Xeroderma, Infant, Sciatica, Weakness, Paced Auditory Serial Addition Test, Infection, Fetus, Leukopenia, AES, Neuropathic pain, Sciatic nerve, Risk, Medical imaging, Vaccine, Dietary supplement, Fever

CAPItello-291 is evaluating the efficacy of capivasertib in combination with FASLODEX versus placebo plus FASLODEX for the treatment of locally advanced (inoperable) or metastatic HR-positive, HER2-low or negative breast cancer.

Key Points: 
  • CAPItello-291 is evaluating the efficacy of capivasertib in combination with FASLODEX versus placebo plus FASLODEX for the treatment of locally advanced (inoperable) or metastatic HR-positive, HER2-low or negative breast cancer.
  • Capivasertib is an investigational oral treatment currently in Phase III trials for the treatment of multiple subtypes of breast cancer, prostate cancer and a Phase II trial for hematologic malignancies.
  • Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION).
  • Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer.

InventHelp Inventor Develops a Convenient On the Go Toothbrush (CHK-339)

Retrieved on: 
Thursday, December 15, 2022
Travel, Gingivitis, Incidence, Breathe Me, Sale, EASY, Multimedia, Dentistry

With this you won't have to worry about packing individual oral care products while on the go."

Key Points: 
  • With this you won't have to worry about packing individual oral care products while on the go."
  • This patent-pending invention eliminates the need to carry oral care products separately making it easier to brush teeth while away from home.
  • This may increase oral care habits which could reduce the incidence of halitosis, cavities, and gingivitis and allows children to practice oral hygiene without assistance.
  • This convenient, practical and easy to use device would provide peace of mind that individuals have fresh breath and clean teeth.

Vapotherm Announces NYSE Continued Listing Standard Notice Related to Stock Price

Retrieved on: 
Tuesday, December 6, 2022
Surgery, Medical Devices, Hospitals, Health, Medical Supplies, Security (finance), Breathe Me, Food, Calendar, VAPO, Regulation, Patient, Gas, Notice, NYSE, COVID-19, Failure, Hypoxemia, Food and Drug Administration, Regulation Fair Disclosure, Patent, Risk, Vapotherm

As set forth in the Notice, as of November 29, 2022, the 30-trading day average closing share price of the Companys common stock was $0.98 per share.

Key Points: 
  • As set forth in the Notice, as of November 29, 2022, the 30-trading day average closing share price of the Companys common stock was $0.98 per share.
  • As of December 5, 2022, the closing share price of the Companys common stock was $1.62 per share and the 30-trading day average closing share price of the Companys common stock was $1.01.
  • The Notice has no immediate impact on the listing of the Companys common stock, which will continue to trade on the NYSE during the applicable cure period, subject to all other listing requirements of the NYSE.
  • The .BC indicator will be removed at such time as the Company regains compliance with all continued listing standards.

SpliSense Initiates Phase 1/2 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis

Retrieved on: 
Wednesday, December 14, 2022
Inhalation, Breathe Me, Eleazar Sukenik, Idiopathic pulmonary fibrosis, Cystic fibrosis, CFTR, Doctor of Philosophy, IPF, Urinary tract infection, Patient, Research, Hebrew University of Jerusalem, Pulmonology, Disease, ASO, Cystic Fibrosis Foundation, RNA transfection, Safety, Asos, Tissue, Life expectancy, Pharmacokinetics, RNA, Mutation, Pharmaceutical industry, Vaccine

The Phase 1/2 placebo-controlled, doubleblind, randomized study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of SPL84 consists of two parts.

Key Points: 
  • The Phase 1/2 placebo-controlled, doubleblind, randomized study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of SPL84 consists of two parts.
  • "CF is a debilitating disease, leading to frequent lung infections, breathing difficulties and reduced life expectancy," said Gili Hart, PhD, Chief Executive Officer, SpliSense.
  • The Company's pioneering platform harnesses ASOs for treatment of unmet cystic fibrosis mutations and large pulmonary diseases including muco-obstructive diseases and IPF.
  • Investors in the Company include Orbimed, Israel Biotech Fund, Biotel Limited, Integra Holdings and the Cystic Fibrosis Foundation.

Accord Healthcare Adds Generic Drug for Use in Treating Leukemia and Non-Hodgkin's Lymphoma

Retrieved on: 
Wednesday, December 7, 2022
CLL, Heart, Food, Rash, Teva, Cough, NHL, Patient, Diarrhea, Chronic lymphocytic leukemia, Research, Food and Drug Administration, Nausea, Aplastic anemia, Headache, United States National Library of Medicine, Fatigue, FDA, Vomiting, Injection, Breathe Me, US Foods, MedlinePlus, Pharmacist, Anaphylaxis, Growth, Constipation, AP, Safety, Purging disorder, Accord, National library, Infection, Tumor lysis syndrome, Rituximab, Intas Biopharmaceuticals, MEDLINE, Pharmaceutical industry, Fever, Bendamustine

DURHAM, N.C., Dec. 7, 2022 /PRNewswire/ -- Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Bendamustine Lyo. Injection to its line of chemotherapy drugs. Accord's product is AP rated to Teva's Treanda® and is being offered in both 25-mg and 100-mg vials.

Key Points: 
  • DURHAM, N.C., Dec. 7, 2022 /PRNewswire/ -- Accord Healthcare, Inc. , a leading generic pharmaceutical company, has added Bendamustine Lyo.
  • Accord Healthcare, a wholly owned subsidiary of Intas Pharmaceuticals, is a leading generic pharmaceutical company.
  • Accord Healthcare combines its advanced manufacturing technology with in-house research to produce highly complex, affordable, and essential medicines.
  • Accord Healthcare's forward-thinking, innovative approach, and its resolve to help patients remains at the heart of everything they do.